WASHINGTON, Jan. 21 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration introduced a draft guidance that recommends using minimal residual disease and complete response as primary endpoints in clinical trials for multiple myeloma treatments. This move is intended to speed up the delivery of drug and biological products to patients by utilizing more sensitive markers of treatment success.

Multiple myeloma is a malignancy of the plasma cells and re . . .

Click here for more information about our products